Document Detail


Prevention of haemarthrosis in a murine model of acute joint bleeding.
MedLine Citation:
PMID:  19149856     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preservation of normal joint function in patients with haemophilia is a goal of modern therapy. Regular injections of anti-haemophilic factor concentrate reduce the risk of joint bleeding, the optimal regimen for which remains under investigation. The goals of the experiment described here are: (i) to assess the capacity of a murine model of severe haemophilic arthropathy to predict the likelihood of success of a test product to prevent joint bleeding and the complications that follow and (ii) to compare the effectiveness of recombinant human activated factor VII (rFVIIa) to recombinant human factor VIII (rFVIII) to prevent acute joint bleeding in the mouse model of haemarthrosis. Mice lacking expression of FVIII received a single intravenous injection of human rFVIII (280 U kg(-1)), rFVIIa (10 mg kg(-1)) or vehicle prior to blunt trauma injury to the knee joint. Mice receiving rFVIII and rFVIIa developed less injury-induced joint bleeding, swelling and loss of range of motion compared to mice pretreated with vehicle. Despite the reduction in clinical symptoms, synovial hyperplasia was evident in all groups after 7 days although less pronounced in mice receiving rFVIII and rFVIIa. The data under these experimental conditions demonstrate: (i) that this model can be used to evaluate novel therapies designed to prevent joint bleeding (prophylaxis) and (ii) both rFVIII and rFVIIa reduced acute haemarthrosis but did not completely prevent synovitis, the sequelae of blood induced joint injury.
Authors:
L A Valentino; N Hakobyan; T Kazarian; B B Sorensen; M Tranholm
Related Documents :
25102956 - Metabolic demands of law enforcement personal protective equipment during exercise tasks.
24435816 - One-minute exercise is best for evaluation of post-exercise exhaustion in myasthenia gr...
24841496 - The role of exercise testing in pediatric cardiology.
24315956 - Exercise & sports science australia (essa) position statement on exercise prescription ...
9302346 - Magnesium abolishes inadequate kinetics of frequency adaptation of the q-at interval in...
3751466 - Circulating growth hormone forms in type 1 diabetic subjects: comparison with normal su...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  15     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-08-04     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  314-9     Citation Subset:  IM    
Affiliation:
The RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics, Rush University Medical Center, Chicago, IL, USA. lvalentino@rush.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Disease Models, Animal*
Drug Evaluation / methods
Factor VIII / therapeutic use
Factor VIIa / therapeutic use
Hemarthrosis / etiology,  pathology,  prevention & control*
Hyperplasia / pathology,  prevention & control
Knee Injuries / complications,  pathology
Mice
Mice, Knockout
Recombinant Proteins / therapeutic use
Synovial Membrane / pathology
Synovitis / pathology,  prevention & control
Wounds, Nonpenetrating / complications,  pathology
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 9001-27-8/Factor VIII; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombin generation assay: a useful routine check-up tool in the management of patients with haemoph...
Next Document:  Individual, social, environmental, and physical environmental correlates with physical activity amon...